Sukanya Chaikittisilpa MD*, Surasak Angsuwathana MD**, Somsak Chaovisitsaree MD***, Mayuree Jirapinyo MD****, Kittisak Wilawan MD*****, Krasean Panyakhamlerd MD*, Unnop Jaisamrarn MD*, Kitirat Techatraisak MD**, Nuntana Morakote BSc, MPH***, Charnchai Suchartwatnachai MD****, Worapong Kongmephol MD*****, Nimit Taechakraichana MD*
Affiliation : * Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand ** Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand *** Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand **** Department of Obstetrics and Gynecology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand ***** Department of Obstetrics and Gynecology, Faculty of Medicine, Phramongkutklao Hospital, Bangkok, Thailand
Objectives: To investigate the efficacy and tolerability of the oral hormone replacement therapy (HRT) containing 1 mg
estradiol (E2) plus 2 mg drospirenone (DRSP) in Thai women with postmenopausal symptoms.
Material and Method: Fifty-five Thai women with postmenopausal symptoms participated in this multicenter, open-label,
non-comparative Phase IV study. The primary endpoint was the reduction of hot flushes after 12 weeks of treatment.
Secondary endpoints included changes in frequency and intensity of menopausal symptoms as well as safety assessments after
4, 8, and 12 weeks of treatment.
Results : Treatment with 1 mg E2 plus 2 mg DRSP reduced the frequency of hot flushes in 94.6% of women at the end of the
12-week treatment period. In 60% of women, the frequency of hot flushes was reduced to 10% or less, compared to baseline
findings and 49.1% of women had no remaining hot flushes. Other postmenopausal symptoms such as vaginal dryness,
urinary incontinence, dysuria, and dyspareunia improved. The most common adverse events were vaginal bleeding or
spotting and breast tenderness.
Conclusion : The oral HRT of 1 mg E2 plus 2 mg DRSP was effective and well tolerated by Thai women suffering from
postmenopausal symptoms.
Keywords : Drospirenone, Estradiol, Hormone replacement therapy (HRT), Menopause
JOURNAL OF THE MEDICAL ASSOCIATION OF THAILAND
4th Floor, Royal Golden Jubilee Building,
2 Soi Soonvijai, New Petchburi road,
Bangkok 10310, Thailand.
Phone: 0-2716-6102, 0-2716-6962
Fax: 0-2314-6305
Email: editor@jmatonline.com
» Online Submissions » Author Guidelines » Copyright Notice » Privacy Statement
» Journal Sponsorship » Site Map » About this Publishing System
© MEDICAL ASSOCIATION OF THAILAND. All Rights Reserved. The content of this site is intended for health professionals.